APAC Tumor Ablation Market

APAC Tumor Ablation Market Size (2022 to 2027)

The size of the tumor ablation market in the Asia Pacific is predicted to be worth USD 0.20 Billion by 2027 from USD 0.09 Billion in 2022, growing at a CAGR of 16.3% from 2022 to 2027.

The increasing prevalence of cancer across the APAC is driving the Tumor ablation market. Also, the rising demand for minimally invasive tumor ablation techniques and safer therapeutics options augment the market growth during the forecast period. In addition, the rising number of initiatives taken by the government for creating awareness among the people and increasing investment by the government and private organizations are encouraging market growth. 

The demand for minimally invasive cancer treatments has been increased significantly in the recent past. As a result, key market participants in this region invest in developing technological advancements in Tumor ablation to enhance cost-effectiveness, portability, and accuracy. The advantages of this technology are the improved volume of tumor ablation, high-temperature stability, minimal ablation pain, and optimum cystic mass heating. Therefore, this segment's growth is likely to be aided by such benefits.

The senior population is further accelerating the market growth, as the growing geriatric population is more prone to various chronic diseases, such as cancer, diabetes, and others. Emerging market entrants and major manufacturers, on the other hand, are actively spending in R&D to create innovative products that will expand the clinical application profile of the tumor ablation market. Further, the increasing inclination of surgeons and patients towards minimally invasive procedures owing to the advantages like speedy recovery, patient comfort, and reduced work time area unit the factors expected to drive the market. Moreover, the increasing population in developing countries such as India and China provides lucrative growth opportunities to the market players and contributes to the APAC regional market growth. 

Various governments' cost-cutting initiatives and continuing healthcare reforms are expected to hinder the tumor ablation market's expansion during the forecast period. In addition, the tumor ablation market will face a challenge as regulatory standards become more stringent, resulting in a considerable increase in product launch gestation periods.

This research report on the APAC tumor ablation market has been segmented and sub-segmented into the following categories:

By Technology: 

• Radiofrequency Ablation Devices
• Microwave Ablation Devices
• Cryoablation Devices
• Other Ablation Devices

By Treatment: 

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation

By Application: 

• Liver Cancer
• Breast Cancer
• Lung Cancer
• Prostrate Metastasis
• Other Cancer

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, the Asia Pacific is estimated to be the fastest-growing region in the global market due to the high population base and favorable economic developments in the area.

The China tumor ablation market is the largest in the Asia Pacific region, accounting for a significant share due to its massive population. Furthermore, the market is likely to grow due to its higher purchasing parity, technological advancement in Tumor ablation, and growing healthcare expenditure. 

In contrast, the Indian tumor ablation market is estimated to be the fastest-growing due to increasing government support and healthcare spending.

On the other hand, countries like Japan and Australia are more likely to witness a promising share in the tumor ablation market and contribute to the Asia Pacific regional market growth. 

KEY MARKET PLAYERS:

Companies playing a promising role in the APAC tumor ablation market profiled in this report are Medtronic Plc., Boston Scientific Corporation, Angiodynamics, Mermaid Medical, HealthTronics, Galil Medical Inc., EDAP TMS S.A., SonaCare Medical, Misonix, Inc. and Neuwave Medical, Inc.